ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

  • 1
  • 2
  • 3
  • …
  • 87
  • Next Page »
Search Again »
  • Abstract Number: 0017 • ACR Convergence 2024

    Syndecan-1 Plays a Role in the Pathogenesis of Sjögren’s Syndrome by Inducing B-cell Chemotaxis Through CXCL13-heparan Sulfate Interaction

    Sang Jin Lee1, Nan Young Lee2, Eun Joo Lee3, Ji Ae Jang3, Gun Woo Kim3 and Eon Jeong Nam2, 1Kyungpook National University Hospital, Daegu, Republic of Korea, 2Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea, 3Daegu Fatima Hospital, Daegu, Republic of Korea

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a prototypical autoimmune disorder with lymphocytic infiltration of exocrine and non-exocrine epithelia, where complex interactions between innate and adaptive…
  • Abstract Number: 0154 • ACR Convergence 2024

    Chronic Sinusitis Predicting Interstitial Lung Disease in Sjögren’s Syndrome: A Comprehensive USA Population Study (2004-2024)

    Brian Schonewald1, Ross summer2, Giorgos Loizidis2 and Christopher Xie3, 1Thomas Jefferson University Hospital, Ardmore, PA, 2Thomas Jefferson University, Philadelphia, PA, 3Thomas Jefferson University, Philadelphia

    Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disorder primarily affecting the exocrine glands, but it also impacts various parts of the respiratory system, including…
  • Abstract Number: 0451 • ACR Convergence 2024

    Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome

    Juan J. Fierro1, Mirthe Schoots1, Silvia Liefers1, Berber Doornbos-van der Meer2, Gilles Diercks1, Hendrika Bootsma3, Jelmer R. Prins1, Johanna Westra1 and Karina de Leeuw4, 1University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, 2University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 3Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 4University Medical Center Groningen, Groningen, Groningen, Netherlands

    Background/Purpose: SLE, primary Sjögren’s disease (pSjD) and APS are systemic rheumatic diseases (SRD) that mainly affect women of childbearing age and have been associated with…
  • Abstract Number: 0620 • ACR Convergence 2024

    Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren’s Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial

    Benjamin A. Fisher1, Hendrika Bootsma2, Vibeke Strand3, Wan-Fai Ng4, Thomas Wegman5, Brandon Becker6, Jiyoon Choi6, Antoine Sreih6, Leo Chen7, Antonia Christodoulou6 and Eric Morand8, 1University of Birmingham, Birmingham, United Kingdom, 2Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 3Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 4Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, 5Bristol Myers Squibb, Beaver Falls, PA, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Richmond, BC, Canada, 8School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

    Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to…
  • Abstract Number: 0884 • ACR Convergence 2024

    Genetic Architecture Divergence in Sjögren’s Disease Subphenotypes and Populations: Genome-wide Association Study of Ro/SSA+ and Ro/SSA- Cases in European Populations

    Marcin Radziszewski1, Astrid Rasmussen2, Bhuwan Khatri2, Kandice Tessneer2, Elena Pontarini3, Michele Bombardieri4, Maureen Rischmueller5, Marie Wahren-Herlenius6, Marika Kvarnström6, Torsten Witte7, Hendrika Bootsma8, Gwenny Verstappen9, Frans Kroese9, Arjan Vissink10, Sarah Pringle9, Athanasios Tzioufas11, Clio Mavragani12, Alan Baer13, Marta Alarcon-Riquelme14, Javier Martin15, Xavier Mariette16, Gaetane Nocturne16, Jacques-Olivier Pers17, Jacques-Eric Gottenberg18, Wan-Fai Ng19, Caroline Shiboski20, Kim Taylor21, Lindsey Criswell22, Blake M. Warner23, A. Darise Farris2, Judith James2, Robert Hal Scofield2, Joel Guthridge2, Daniel Wallace24, Swamy Venuturupalli25, Michael Brennan26, Juliana Imgenberg-Kreuz27, Lars Rönnblom27, Eva Baecklund27, Maija-Leena Eloranta27, Lara Aqrawi27, Øyvind Palm28, Johan Brun29, Daniel Hammenfors29, Malin Jonsson29, Silke Appel29, Sara Magnusson Bucher30, Helena Forsblad-d'Elia31, Thomas Mandl32 and Christopher Lessard2, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Queen Mary University of London, London, United Kingdom, 4Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 5RheumatologySA, Adelaide, Australia, 6Karolinska Institutet, Stockholm, Sweden, 7Dept of Immunology and Rheumatology, Hannover, Germany, 8Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 9University Medical Center Groningen, Groningen, Netherlands, 10University Medical Center Groningen, Leek, Netherlands, 11LAIKO HOSPITAL, Athens, Greece, 12National and Kapodistrian University of Athens, Athens, Greece, 13Johns Hopkins University School of Medicine, Baltimore, MD, 14Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 15Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, 16Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 17University of Brest, Brest, France, 18Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 19Institute of Cellular Medicine, Newcastle University, Gateshead, United Kingdom, 20University of California San Francisco, San Francisco, CA, 21University of California, San Francisco, CA, 22Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, 23National Institutes of Health, Bethesda, MD, 24Cedars Sinai Medical Center, Studio City, CA, 25Attune Health, Beverly Hills, CA, 26Atrium Health Carolinas Medical Center, Charlotte, NC, 27Uppsala University, Uppsala, Sweden, 28University of Oslo, Oslo, Norway, 29University of Bergen, Bergen, Norway, 30Universitetssjukhuset, Orebro, Sweden, 31University of Gothenburg, Gothenburg, Sweden, 32Lund University, Malmö, Sweden

    Background/Purpose: Sjögren's disease (SjD) is a complex systemic autoimmune disease with 22 genome-wide significant (GWS) risk loci [1]. Historically, genomic research has focused on populations…
  • Abstract Number: 0889 • ACR Convergence 2024

    Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics

    Tomás Gomes1, Matilde Bandeira2, Rui do Amaral Vieira1, Bianca Correia1, Sofia Barreira3, Pedro Gaspar4, Rita Cruz-Machado5, Beatriz Filipe1, Pedro Ávila-Ribeiro1, Filipa Ribeiro1, Bruno Vidal1, Beatriz Val1, Filipa Costa6, Ana Teodósio Chícharo7, Augusto Silva1, Manuel Silvério-Antonio1, João Forjaz Lacerda1, João Eurico Fonseca1, Dolores López Presa8, Nikita Khmelinskii1, Saumya Kumar9, Luis Graca1 and Vasco C. Romão10, 1Instituto de Medicina Molecular (iMM Lisboa), Lisboa, Portugal, 2Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, 3Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisbon, Portugal, 4Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, 5Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisboa, Portugal, 6Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, 7Unidade Local de Saúde do Algarve, Hospital de Faro, Faro, Portugal, Faro, Portugal, 8Pathology Department, Unidade Local de Saúde de Santa Maria, Lisbon Academic Medical Centre, Lisboa, Portugal, 9TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany, Hannover, Germany, 10Rheumatology Department, ULS Santa Maria & Rheumatology Research Unit, Instituto Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

    Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disease that primarily targets salivary and lacrimal glands, causing tissue deterioration and loss of function. Disease progression…
  • Abstract Number: 0892 • ACR Convergence 2024

    Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR

    Tommi C. Taylor1, Sri Ramarathinam2, Shan Zou Chung2, Kirti Pandey2, Ananth Aditya Jupudi1, Bhuwan Khatri3, Sherri Longobardi3, Charmaine Lopez-Davis3, Astrid Rasmussen3, Kiely Grundahl3, Robert Hal Scofield3, Christopher Lessard3, Linda F. Thompson3, Anthony W. Purcell2 and A. Darise Farris3, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Monash University, Clayton, Victoria, Australia, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Sjögren’s Disease (SjD) is characterized by aberrant autoimmune reactions in lacrimal and salivary glands (SG) leading to severe dryness. Evidence for B cell help…
  • Abstract Number: 0931 • ACR Convergence 2024

    Salivary Granular Convoluted Tubules Contribute to Maintain Tissue-specific Tolerance – Implications for the Development of Murine Sjögren´s Syndrome

    Xiaomei Shan1, Clara Reichardt1, Marco Munoz Becerra1, Aleix Rigau2, Lena Müller3, Anne Zeitler1, Jasmin Knopf4, Gerhard Grossmayer1, Martin Herrmann1, Christine Schauer1, Markus Eckstein5, Georg Schett6 and Luis Munoz7, 1Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany, 2Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Medizin Universität Wien, Vienna, Austria, 4Universitätsklinikum Mannheim, Mannheim, Germany, 5Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 6Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 7Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen

    Background/Purpose: Primary Sjögren's syndrome (PSS) is a chronic inflammatory disease affecting exocrine glands with an important systemic autoimmune reaction against some nuclear and membrane bound…
  • Abstract Number: 1048 • ACR Convergence 2024

    Self-Perception of Oral Health and Habits in Patients with Sjögren’s Syndrome, Rheumatoid Arthritis, and Systemic Lupus Erythematosus

    Karina Palomo-Arnaud1, Gabriel Figueroa-Parra2, Angel Kevin Garza-Elizondo1, Margarita Isabel Alarcon Jarquin3, Jesus Cardenas-de la Garza4, Dionicio Galarza-Delgado5 and Janett Riega Torres2, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, 4Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 5UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Oral manifestations, especially periodontitis and tooth loss, are highly prevalent in patients with rheumatic diseases. Sjogren’s syndrome (SS), rheumatoid arthritis (RA), and systemic lupus…
  • Abstract Number: 1247 • ACR Convergence 2024

    Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren’s Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations

    Sarah N. Ali1, Dorothee Oberdhan1, Michelle M. Richardson1, Jordan Amorelli2, Amanda Martini2 and Jennifer Dandy2, 1Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, 2Real Chemistry, New York, NY

    Background/Purpose: Patients with Sjögren’s Syndrome (SS) often undergo a prolonged and complex path to diagnosis and experience symptom, disease and treatment burdens with multiple co-morbid…
  • Abstract Number: 1250 • ACR Convergence 2024

    Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren’s Disease

    Suzanne Arends1, Jiyoon C. Choi2, Brandon Becker2, Teresa Edwards3, Antoine Sreih4, Antonia Christodoulou4 and Vibeke Strand5, 1Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Bristol Myers Squibb, Princeton, 3RTI International, Research Triangle Park, NC, 4Bristol Myers Squibb, Princeton, NJ, 5Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA

    Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration of the endocrine glands. Globally, SjD affects between 0.01% and 0.05%…
  • Abstract Number: 1406 • ACR Convergence 2024

    Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease

    Negaar Goudarzi1, Loïc Meudec2, Juliette Pascaud2, Fanny Jaulin3, Quentin Pascal4, Thierry Lazure5, Sacha E Silva Saffar2, Xavier Mariette6 and Gaetane Nocturne6, 1University Paris-Saclay, Le Kremlin Bicêtre, France, 2University Paris Saclay, Le Kremlin Bicetre, France, 3Institut Gustave Roussy, Villejuif, France, 4CEA, Fontenay aux roses, France, 5APHP. Université Paris-Saclay, Hôpital Bicêtre, Anatomie et cytologie pathologiques, Paris, France, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease that manifests as glandular dryness and systemic symptoms. Salivary gland epithelial cells (SGEC) are pivotal in…
  • Abstract Number: 1408 • ACR Convergence 2024

    Color Doppler Ultrasound Is a Reliable Method for Imaging the Lacrimal Glands in Patients with Suspected Sjögren’s Disease

    Ting Yang1, Neils Sluijpers1, Jolien van Nimwegen1, Alja Stel1, Adriaan Coumou1, Frans Kroese2, Hendrika Bootsma3, Konstantina Delli1 and Sarah Pringle2, 1UMCG, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands, 3Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands

    Background/Purpose: As a widely available, non-invasive and repeatable technique, ultrasound has already been used for the examination of irregularities of the major salivary glands. However,…
  • Abstract Number: 1409 • ACR Convergence 2024

    Salivary Organoids Contain More Diverse Epithelial and Less Mesenchymal Cells Than Adherent Cultures: Choose Your Sjögren’s Disease Research Tool Carefully

    Ting Yang1, Abel Soto Gamez1, Janneke Terpstra1, Hendrika Bootsma2, Arjan Vissink1, Frans Kroese3 and Sarah Pringle3, 1UMCG, Groningen, Netherlands, 2Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 3University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: The majority of the critical pieces of work probing the involvement of the salivary gland (SG) epithelium in Sjogren’s Disease (SjD) employ salivary gland…
  • Abstract Number: 1410 • ACR Convergence 2024

    Using Social Listening to Understand the Patient Voice: The Daily Impacts of Sjögren’s Disease

    Zachary Cline1, Maurice Flurie1, Colton Flowers1, Enming Zhang1, Annie Lau-Kilby2, Julia Taylor2, Chiara Baldini3, Ilias Alevizo2, Kristina Davidson2, Christopher DeFelice1 and Maria Picone1, 1TREND Community, Philadelphia, PA, 2Amgen Inc., Thousand Oaks, CA, 3University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy

    Background/Purpose: Insights into the everyday burden and management of a disease relies on patient perspectives, and social media groups focused on specific diseases offer a…
  • 1
  • 2
  • 3
  • …
  • 87
  • Next Page »
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology